Related Experiment Videos
Clinical outcomes in juvenile dermatomyositis
1Division of Rheumatology, Department of Pediatrics, Hospital for Sick Children, Toronto, Ontario, Canada.
Current Opinion in Rheumatology
|November 1, 2002
Summary
Juvenile dermatomyositis is a chronic inflammatory disease affecting children
Area of Science:
- Pediatric Rheumatology
- Dermatology
- Immunology
Background:
- Juvenile dermatomyositis (JDM) is a rare autoimmune disease of unknown cause.
- It primarily impacts the muscles and skin in children.
- Systemic involvement can affect the gastrointestinal tract, lungs, and heart, with calcinosis occurring in a third of cases.
Purpose of the Study:
- To provide a comprehensive overview of juvenile dermatomyositis.
- To discuss current therapeutic strategies and outcomes.
Main Methods:
- Literature review of juvenile dermatomyositis.
- Analysis of disease incidence, clinical manifestations, and treatment responses.
Main Results:
- JDM affects 2-3 per million children annually.
- Corticosteroids are the primary treatment, with additional immunosuppressants used for resistance.
- Modern treatments improve functional outcomes, though the disease often remains chronic with sequelae.
Conclusions:
- Juvenile dermatomyositis requires ongoing management.
- While treatments have advanced, long-term sequelae and chronic disease persist in many pediatric patients.